Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine

Fudan University224 enrolled

Overview

This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib plus Vinorelbine versus Lapatinib plus Capecitabine in patients with previously treated HER2-positive metastatic breast cancer.

Study Type

OBSERVATIONAL

Enrollment

224

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive. * Patients were previously treated with trastuzumab in the advanced setting and a taxane in any setting. * Patients received lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2) or pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days) for at least one cycle, starting from Jun 2015 to Jan 2021. * Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions. Exclusion Criteria: * Incomplete medical history

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, China

Outcomes

Primary Outcomes

PFS

Progression free survival

Time frame: 6 weeks

Secondary Outcomes

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.